Who Benefits From Immunotherapy?
Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
Progress Against Cancer
Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
A new report from the American Association for Cancer Research explores how the COVID-19 pandemic affected cancer patients, researchers and care providers.
A new kind of blood test could help detect brain cancers at an earlier stage.
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Metastatic cancer patients nearing death continue to receive high-dose radiation despite guidelines advising against it, and new standards are likely to reduce racial disparities in lung cancer screening.
Each year in the United States, about 14,480 women are diagnosed with cervical cancer, and about 4,290 women die of the disease. Survivors often face a lifetime of complications, from infertility to pain and bleeding. ...
Women with breast cancer who choose fertility preservation have treatment outcomes similar to women who don’t undergo fertility preservation.
Researchers aim to minimize disease relapses by targeting multiple proteins.
The year 2021 defied our expectations in a variety of ways. The delta and omicron COVID-19 variants imposed unprecedented challenges on the health care system and threatened our hopes of an end to the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More